All NewsEducationTVBrokers
Equities & FundsCrypto & Digital AssetsAI & TechnologyBusiness & CorporateUS Politics & PolicyGeopolitics & Global RiskMacro, Rates & FXCommodities & EnergyEuropean Politics & MarketsAsia-PacificReal Estate & Property
All NewsHome
← Back to AI & Technology

Nanodrug Trials Show Potential for Permanent Bad Cholesterol Reduction

Created at 9 Sep · 3:05 AM1 source↑ Market-relevant
IN SHORT

New nanodrug trials in the US and China suggest a single injection could permanently eliminate "bad" cholesterol. The drug targets PCSK9, a protein linked to high cholesterol levels, offering a potential one-time cure for hypercholesterolemia.

Key Numbers

1number of injections required

Who's Involved

US and China
conducting trials for a new nanodrug
Nanodrug Trials Show Potential for Permanent Bad Cholesterol Reduction

↳ Why This Matters

This nanodrug could represent a paradigm shift in treating high cholesterol, potentially offering a permanent solution rather than lifelong medication and significantly reducing the risk of heart disease and stroke.

Key facts

  • A new nanodrug developed in the US and China targets PCSK9.
  • The drug is designed to permanently reduce LDL cholesterol.
  • The treatment involves a single injection.
  • Early trials suggest a high success rate in eliminating "bad" cholesterol.

Researchers in the United States and China have developed a nanodrug that shows potential for permanently eliminating "bad" cholesterol with a single injection. The experimental treatment targets the PCSK9 protein, which plays a key role in regulating cholesterol levels. By inhibiting PCSK9, the drug aims to drastically reduce LDL cholesterol, offering a potential one-time cure for individuals suffering from hypercholesterolemia. Early trial results are reportedly very promising, suggesting a significant breakthrough in cardiovascular disease treatment.

Frequently asked questions

"Bad" cholesterol refers to LDL (low-density lipoprotein) cholesterol, high levels of which can lead to plaque buildup in arteries, increasing the risk of heart disease and stroke.

The nanodrug targets and inhibits the PCSK9 protein, which normally degrades LDL receptors in the liver. By blocking PCSK9, more LDL receptors remain active, leading to a significant reduction in LDL cholesterol from the bloodstream.

A single-injection treatment would be a major advancement, potentially eliminating the need for daily pills and improving patient adherence and long-term outcomes for cholesterol management.

What Happens Next

01Further clinical trials are needed to confirm efficacy and safety.
02Regulatory approval processes will follow successful trial outcomes.
CME Headlines
  • Risk Management and Monitoring Notice: Multi-Factor Authentication Updates - September 12
    3 Sep · 5:00 AM

How It Developed

A novel nanodrug targeting PCSK9 has shown promise in early trials.
The drug aims to permanently reduce "bad" cholesterol levels.
Trials have been conducted in both the United States and China.
The treatment involves a single injection.
Researchers are optimistic about the potential for a permanent cure for high cholesterol.

Sources

T1
US, China trials suggest a single nanodrug shot might stop bad cholesterol foreverSouth China Morning Post

Related Stories

Top chipmakers adopt ASML's advanced EUV machines, agree to photomask standard change
8 Sep · 7:16 PM
Japan consortium develops perovskite solar cells with 50% longer lifespan
8 Sep · 9:26 AM
Tesla's rare-earth-free motor could disrupt China's dominance
8 Sep · 1:21 PM
Eggshell-inspired aluminum arrays show promise for spacecraft debris protection
8 Sep · 4:26 PM
China's top court issues AI guidelines on deepfakes and privacy
8 Sep · 11:21 AM